|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kan Z, Zheng H, Liu X, Li S, Barber TD,
Gong Z, Gao H, Hao K, Willard MD, Xu J, et al: Whole-genome
sequencing identifies recurrent mutations in hepatocellular
carcinoma. Genome Res. 23:1422–1433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hennedige TP, Neo WT and Venkatesh SK:
Imaging of malignancies of the biliary tract-an update. Cancer
Imaging. 14:142014.PubMed/NCBI
|
|
7
|
Jain A, Kwong LN and Javle M: Genomic
profiling of biliary tract cancers and implications for clinical
practice. Curr Treat Options Oncol. 17:582016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jain A and Javle M: Molecular profiling of
biliary tract cancer: A target rich disease. J Gastrointest Oncol.
7:797–803. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang Z, Jhunjhunwala S, Liu J, Haverty
PM, Kennemer MI, Guan Y, Lee W, Carnevali P, Stinson J, Johnson S,
et al: The effects of hepatitis B virus integration into the
genomes of hepatocellular carcinoma patients. Genome Res.
22:593–601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sung WK, Zheng H, Li S, Chen R, Liu X, Li
Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, et al: Genome-wide
survey of recurrent HBV integration in hepatocellular carcinoma.
Nat Genet. 44:765–769. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao LH, Liu X, Yan HX, Li WY, Zeng X,
Yang Y, Zhao J, Liu SP, Zhuang XH, Lin C, et al: Genomic and
oncogenic preference of HBV integration in hepatocellular
carcinoma. Nat Commun. 7:129922016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang P, Markowitz GJ and Wang XF: The
hepatitis B virus-associated tumor microenvironment in
hepatocellular carcinoma. Natl Sci Rev. 1:396–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang S, Hu W, Hu J, Wu S, Li J, Luo Y, Cao
M, Zhou H and Jiang X: Hepatitis B virus X protein promotes P3
transcript expression of the insulin-like growth factor 2 gene via
inducing hypomethylation of P3 promoter in hepatocellular
carcinoma. Liver Int. 35:608–619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan J, Clayton M and Feitelson MA:
Hepatitis B virus X antigen promotes transforming growth
factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and
down-regulation of alpha2-macroglobulin. J Gen Virol. 85:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF,
Chang KY, Huang WC, Lin PW, Chiang CW and Chang TT: Hepatitis B
virus X protein upregulates mTOR signaling through IKKβ to increase
cell proliferation and VEGF production in hepatocellular carcinoma.
PLoS One. 7:e419312012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang T, Zhang J, You X, Liu Q, Du Y, Gao
Y, Shan C, Kong G, Wang Y, Yang X, et al: Hepatitis B virus X
protein modulates oncogene Yes-associated protein by CREB to
promote growth of hepatoma cells. Hepatology. 56:2051–2059. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsieh A, Kim HS, Lim SO, Yu DY and Jung G:
Hepatitis B viral X protein interacts with tumor suppressor
adenomatous polyposis coli to activate Wnt/β-catenin signaling.
Cancer Lett. 300:162–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HY, Cho HK, Hong SP and Cheong J:
Hepatitis B virus X protein stimulates the Hedgehog-Gli activation
through protein stabilization and nuclear localization of Gli1 in
liver cancer cells. Cancer Lett. 309:176–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang JD, Kim WR, Coelho R, Mettler TA,
Benson JT, Sanderson SO, Therneau TM, Kim B and Roberts LR:
Cirrhosis is present in most patients with hepatitis B and
hepatocellular carcinoma. Clin Gastroenterol Hepatol. 9:64–70.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dotto GP and Rustgi AK: Squamous cell
cancers: A unified perspective on biology and genetics. Cancer
Cell. 29:622–637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herraez E, Lozano E, Macias RI, Vaquero J,
Bujanda L, Banales JM, Marin JJ and Briz O: Expression of SLC22A1
variants may affect the response of hepatocellular carcinoma and
cholangiocarcinoma to sorafenib. Hepatology. 58:1065–1073. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chaisaingmongkol J, Budhu A, Dang H,
Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y,
Bhudhisawasdi V, Lertprasertsuke N, et al: Common molecular
subtypes among asian hepatocellular carcinoma and
cholangiocarcinoma. Cancer Cell. 32:57–70.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Helleday T, Eshtad S and Nik-Zainal S:
Mechanisms underlying mutational signatures in human cancers. Nat
Rev Genet. 15:585–598. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Totoki Y, Tatsuno K, Yamamoto S, Arai Y,
Hosoda F, Ishikawa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara
T, et al: High-resolution characterization of a hepatocellular
carcinoma genome. Nat Genet. 43:464–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ong CK, Subimerb C, Pairojkul C, Wongkham
S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et
al: Exome sequencing of liver fluke-associated cholangiocarcinoma.
Nat Genet. 44:690–693. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dong H, Zhang L, Qian Z, Zhu X, Zhu G,
Chen Y, Xie X, Ye Q, Zang J, Ren Z and Ji Q: Identification of
HBV-MLL4 integration and its molecular basis in chinese
hepatocellular carcinoma. PLoS One. 10:e01231752015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Zhang J, Yang Z, Kang J, Jiang S,
Zhang T, Chen T, Li M, Lv Q, Chen X, et al: The function of
targeted host genes determines the oncogenicity of HBV integration
in hepatocellular carcinoma. J Hepatol. 60:975–984. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee YY, Mok MT and Cheng AS: Dissecting
the pleiotropic actions of HBx mutants against hypoxia in
hepatocellular carcinoma. Hepatobiliary Surg Nutr. 3:95–97.
2014.PubMed/NCBI
|
|
32
|
Lara-Pezzi E, Majano PL, Yáñez-Mó M,
Gómez-Gonzalo M, Carretero M, Moreno-Otero R, Sánchez-Madrid F and
López-Cabrera M: Effect of the hepatitis B virus HBx protein on
integrin-mediated adhesion to and migration on extracellular
matrix. J Hepatol. 34:409–415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
